Published in J Pharmacol Exp Ther on February 01, 1990
Expression of AT2 receptors in the developing rat fetus. J Clin Invest (1991) 1.89
Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest (1992) 1.28
Nitric oxide and angiotensin II. Glomerular and tubular interaction in the rat. J Clin Invest (1992) 1.19
Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol (1993) 1.19
Endogenous production of angiotensin II modulates rat proximal tubule transport. J Clin Invest (1996) 1.11
Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol (1993) 1.02
Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets. Prog Neurobiol (2007) 0.94
Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol (1993) 0.85
Comparison of the transplacental transfer of enalapril, captopril and losartan in sheep. Br J Pharmacol (1995) 0.80
Comparison of the regional haemodynamic effects of the AT1-receptor antagonists, losartan and EXP 3174, in water-deprived Brattleboro rats. Br J Pharmacol (1993) 0.79
Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension. Proc Natl Acad Sci U S A (1994) 0.79
Effects of the angiotensin type I receptor antagonist, losartan, on systemic and regional vascular responses to lower body negative pressure in healthy volunteers. Br J Clin Pharmacol (1995) 0.75
Involvement of nitric oxide, but not prostaglandins, in the vascular sympathoinhibitory effects of losartan in the pithed spontaneously hypertensive rat. Br J Pharmacol (1996) 0.75
Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet (2011) 10.73
Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med (1978) 9.29
Randomised clinical trial of strategies for improving medication compliance in primary hypertension. Lancet (1975) 7.22
Improvement of medication compliance in uncontrolled hypertension. Lancet (1976) 4.84
Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev (1993) 4.69
Anomalous origin of the left coronary artery from the pulmonary trunk. Its clinical spectrum, pathology, and pathophysiology, based on a review of 140 cases with seven further cases. Circulation (1968) 4.34
Mortality from epilepsy: results from a prospective population-based study. Lancet (1994) 4.31
Control of DNA synthesis genes in fission yeast by the cell-cycle gene cdc10+. Nature (1992) 4.13
Pathway correcting DNA replication errors in Saccharomyces cerevisiae. EMBO J (1993) 3.57
Coordination of expression of DNA synthesis genes in budding yeast by a cell-cycle regulated trans factor. Nature (1991) 3.53
Coordinated regulation of gene expression by the cell cycle transcription factor Swi4 and the protein kinase C MAP kinase pathway for yeast cell integrity. EMBO J (1996) 3.45
A multicopy suppressor gene of the Saccharomyces cerevisiae G1 cell cycle mutant gene dbf4 encodes a protein kinase and is identified as CDC5. Mol Cell Biol (1993) 3.33
SWI6 protein is required for transcription of the periodically expressed DNA synthesis genes in budding yeast. Nature (1992) 3.32
Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet (1995) 3.17
Recovery from chronic fatigue syndrome after treatments given in the PACE trial. Psychol Med (2013) 2.82
Drowning in people with epilepsy: how great is the risk? Neurology (2008) 2.80
P40SDB25, a putative CDK inhibitor, has a role in the M/G1 transition in Saccharomyces cerevisiae. Genes Dev (1994) 2.72
Anaerobic Degradation of Chloroaromatic Compounds in Aquatic Sediments under a Variety of Enrichment Conditions. Appl Environ Microbiol (1989) 2.69
National General Practice Study of Epilepsy: recurrence after a first seizure. Lancet (1990) 2.65
MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg Med Chem Lett (1998) 2.61
Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet (1998) 2.58
Characterization of anaerobic dechlorinating consortia derived from aquatic sediments. Appl Environ Microbiol (1989) 2.57
DNA polymerase II, the probable homolog of mammalian DNA polymerase epsilon, replicates chromosomal DNA in the yeast Saccharomyces cerevisiae. EMBO J (1992) 2.51
Falls in the elderly related to postural imbalance. Br Med J (1977) 2.47
The yeast DNA polymerase I transcript is regulated in both the mitotic cell cycle and in meiosis and is also induced after DNA damage. Nucleic Acids Res (1987) 2.38
Infection of the uterine cervix with Chlamydia trachomatis. J Infect Dis (1978) 2.36
Cloning DPB3, the gene encoding the third subunit of DNA polymerase II of Saccharomyces cerevisiae. Nucleic Acids Res (1991) 2.34
Identification of angiotensin II receptor subtypes. Biochem Biophys Res Commun (1989) 2.23
National General Practice Study of Epilepsy: newly diagnosed epileptic seizures in a general population. Lancet (1990) 2.22
Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Arch Gen Psychiatry (1999) 2.12
Is cardiac resuscitation worthwhile? A decade of experience. N Engl J Med (1972) 2.07
Aetiology of urinary symptoms in sexually active women. Genitourin Med (1986) 2.03
Integrated hospital and community psychiatric services and use of inpatient beds. BMJ (1989) 2.03
The forkhead protein Fkh2 is a component of the yeast cell cycle transcription factor SFF. EMBO J (2000) 1.95
Cranial cruciate ligament rupture. Pathogenesis, diagnosis, and postoperative rehabilitation. Vet Clin North Am Small Anim Pract (1993) 1.89
Results of cardiac resuscitation in 552 patients. Am J Cardiol (1967) 1.88
Expression of the yeast DNA primase gene, PRI1, is regulated within the mitotic cell cycle and in meiosis. Mol Gen Genet (1990) 1.85
Expanded profile of the SHAFT syndrome. J Hand Surg Am (1998) 1.84
Overlapping and distinct roles of the duplicated yeast transcription factors Ace2p and Swi5p. Mol Microbiol (2001) 1.82
Order of function of the budding-yeast mitotic exit-network proteins Tem1, Cdc15, Mob1, Dbf2, and Cdc5. Curr Biol (2001) 1.76
Postsynaptic alpha 1- and alpha 2-adrenoceptors in the circulatory system of the pithed rat: selective stimulation of the alpha 2-type by B-HT 933. Eur J Pharmacol (1980) 1.75
Oral contraceptives, depression, and libido. Br Med J (1971) 1.74
Prazosin and its analogues UK-18,596 and UK-33,274: a comparative study on cardiovascular effects and alpha-adrenoceptor blocking activities. Arch Int Pharmacodyn Ther (1980) 1.69
The Skn7 response regulator of Saccharomyces cerevisiae interacts with Hsf1 in vivo and is required for the induction of heat shock genes by oxidative stress. Mol Biol Cell (2000) 1.69
Stable carbon isotope analysis of nucleic acids to trace sources of dissolved substrates used by estuarine bacteria. Appl Environ Microbiol (1990) 1.67
A post-mortem study of the cholinergic and GABA systems in senile dementia. Brain (1982) 1.62
Involvement of apoptosis in ovarian follicular atresia and postovulatory regression. Endocrinology (1991) 1.61
Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther (1990) 1.60
A Bub2p-dependent spindle checkpoint pathway regulates the Dbf2p kinase in budding yeast. EMBO J (1999) 1.60
The Swi5 transcription factor of Saccharomyces cerevisiae has a role in exit from mitosis through induction of the cdk-inhibitor Sic1 in telophase. Genetics (1997) 1.59
Duration of relapse prevention after cognitive therapy in residual depression: follow-up of controlled trial. Psychol Med (2005) 1.59
Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther (1990) 1.57
Rme1, a negative regulator of meiosis, is also a positive activator of G1 cyclin gene expression. EMBO J (1995) 1.56
Mortality in epilepsy in the first 11 to 14 years after diagnosis: multivariate analysis of a long-term, prospective, population-based cohort. Ann Neurol (2001) 1.56
The Nottingham study of neurotic disorder: comparison of drug and psychological treatments. Lancet (1988) 1.53
Depressive symptoms and oral contraceptives. Br Med J (1970) 1.53
Association of the cell cycle transcription factor Mbp1 with the Skn7 response regulator in budding yeast. Mol Biol Cell (1999) 1.53
Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives. J Med Chem (1991) 1.50
Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AII-1) and PD123177 (AII-2). J Pharmacol Exp Ther (1990) 1.50
Nomenclature for angiotensin receptors. A report of the Nomenclature Committee of the Council for High Blood Pressure Research. Hypertension (1991) 1.48
Cognition and survival: an exploration in a large multicentre study of the population aged 65 years and over. Int J Epidemiol (2001) 1.48
Chronic lead absorption. Result of poor ventilation in an indoor pistol range. JAMA (1975) 1.48
Evaluation of fibular head transposition, lateral fabellar suture, and conservative treatment of cranial cruciate ligament rupture in large dogs: a retrospective study. J Am Anim Hosp Assoc (1996) 1.48
Self-recording of blood pressure in the management of hypertension. Can Med Assoc J (1978) 1.46
Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther (1990) 1.46
The prognosis for seizure control in newly diagnosed epilepsy. N Engl J Med (1984) 1.46
A new class of synthetic auxin transport inhibitors. Plant Physiol (1976) 1.45
Nonpeptide angiotensin II receptor antagonists. Trends Pharmacol Sci (1991) 1.45
Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet (1996) 1.41
alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem (1982) 1.38